100th patient joins ChariotMS trial for multiple sclerosis
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read Moreby Jen Brogan | Nov 10, 2023 | News | 0
The trial is testing whether Mavenclad could benefit upper limb movement in MS patients
Read Moreby Lucy Parsons | Nov 19, 2020 | News | 0
Trial will evaluate whether Mavenclad can slow the rate of upper limb disability progression
Read Moreby Anna Smith | Apr 1, 2019 | News | 0
The drug is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment.
Read Moreby Selina McKee | Feb 13, 2018 | News | 0
Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive.
Read Moreby Selina McKee | Nov 10, 2017 | News | 0
Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
Read Moreby Selina McKee | Oct 27, 2017 | News | 0
Merck has released new data showing a positive benefit-risk profile for its multiple sclerosis drug Mavenclad.
Read Moreby Selina McKee | Sep 21, 2017 | News | 0
Merck’s Mavenclad is now available in the UK and Ireland to treat highly active relapsing multiple sclerosis in adults.
Read Moreby Selina McKee | Aug 25, 2017 | News | 0
Merck’s Mavenclad has bagged approval in the European Union, Norway, Liechtenstein and Iceland to treat highly active relapsing multiple sclerosis.
Read Moreby Selina McKee | Jun 26, 2017 | News | 0
Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
